Compare Novo Nordisk A/S (NVO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Standard Lithium Ltd — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Novo Nordisk A/S is far larger — about 415.3× Standard Lithium Ltd's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Standard Lithium Ltd for 23 Days on average.
| NVO | SLI | |
|---|---|---|
Market Cap | $165.31B | $398.07M |
Volume | 11,432,838 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $5.65 |
52-Week Low | $35.29 | $1.61 |
Typical Hold Time | 116 Days | 23 Days |
Enterprise Value | $179.56B | $260.98M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company is pre-revenue with significant losses, reporting negative EBITDA of $50.53 million for 2025, but has made progress on its South West Arkansas lithium project, targeting a final investment decision by end of 2026. Analyst consensus is unanimously bullish with a $3.83 price target.
The investment case hinges on successful project execution and commercialization, offering substantial upside if milestones are met. Key risks include the capital-intensive nature of lithium production, execution delays, and reliance on future financing, with current cash flow sustained by financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
